AABB's Statements to the Blood Product Advisory Committee

Joint Statement Before BPAC on Cold Stored Platelets for Transfusion (PDF)
Joint Statement Before BPAC on Strategies to Control the Risk of Bacterial Contamination in Platelets for Transfusion (PDF)
Joint Statement Before BPAC on August 2016 Zika Guidance Document (PDF)
Statement Before BPAC on “Blood Donor Deferral Policy for Reducing the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products (PDF)
Joint Statement Before BPAC on FDA “Recommendation for Donor Screening, Deferral and Product Management to Reduce the Risk of Transfusion-Transmission of Zika Virus,” August 2016 Guidance (PDF)
Statement Before BPAC on the Management of Iron Deficiency Associated with Blood Donation (PDF)
Statement Before BPAC on Strategies for Implementation of Testing for Babesia microti in Blood Donors (PDF)

For more information, refer to the comprehensive list of statements and comments to FDA.

Related News

Robert Califf Nominated as FDA Commissioner

November 22, 2021
New York Company Receives Untitled Letter for Marketing Unapproved HCT/Ps

November 17, 2021
ACBTSA to Discuss Recommendations for Solid Organ Donors and Transplant Recipients for HIV, HBV and HCV at December Meeting

November 16, 2021